Digital Agenda

The Society of Hematologic Oncology's Eighth Annual Meeting will be held on September 9-12, 2020 as a virtual event. The focus of the 3.5-day program is state-of-the-art approaches in the field of hematologic malignancies.

The virtual meeting offers participants:

  • live-stream multi-track session broadcast with live lectures, debates, plenary sessions and more
  • ability to engage with other virtual participants and presenters
  • 'live', virtual poster session and ongoing access to the poster hall for viewing, discussions and collaborations
  • access to the virtual exhibit hall for discussions, information and FREE give-aways
  • on-demand recordings for 4-months following the annual meeting
  • digital copy of speakers' slides, final program and abstract proceedings published in the official CLML journal supplement
  • CME credits for physicians and CNE credits for nurses

You may view the SOHO 2020 session line-up in the following Digital Agenda. Those that have registered may select the link to join the session directly. Note that all times in the program are listed in Central Daylight Time (CDT) which is 5 hours behind Coordinated Universal Time (UTC -5).

Wednesday, September 9, 2020
6:45 AM - 7:45 AM (CDT)

MTP Session I: AML        

Session Chair: Vitae Vyas        

  • IDH Inhibition  |  Stéphane De Botton, MD  |  Institut de Cancérologie Gustave Roussy, Paris, France
  • FLT3 Inhibition  |  Catherine Smith, MD  |  University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA
  • Approaches to Understand Mechanisms of Resistance and Response To AML Therapies Using Single Cell Approaches  |  Vitae Paresh Vyas, MRCPath, FRCP, FRCPath  |  Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
Go To Session
6:45 AM - 7:45 AM (CDT)

MTP Session II: ALL

Session Chair: Ching-Hon Pui        

  • How The COG Is Approaching The High Risk Patient With ALL – Incorporation Of Immunotherapy Into Frontline Treatment  |  Jennifer McNeer, MD, MS  |  The University of Chicago Medicine, Chicago, Illinois, USA
  • Management of Toxicity in AYAs with ALL  |  Kjeld  Schmiegelow, MD  |  Copenhagen University Hospital, Copenhagen, Denmark
  • How to Use an MRD Result in AYAs Receiving Pediatric Regimens?  |  Aaron Logan, MD, PhD  |  UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA
Go To Session
6:45 AM - 7:45 AM (CDT)

MTP Session III: NHL  

Session Chair: Nathan Fowler        

  • Role of Transplant in Lymphoma  |  Sonali M. Smith, MD, FASCO  |  The University of Chicago, Chicago, Illinois, USA
  • CNS Lymphoma  |  Christopher R Flowers, MD, MS  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  • What is the Optimal Frontline Regimen in FL  |  Nathan H. Fowler, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Go To Session
6:45 AM - 7:45 AM (CDT)

MTP Session IV: NHL

Session Chair: Laurie Sehn        

  • Hodgkin Lymphoma  |  Pier Luigi Zinzani, MD  |  University of Bologna, Bologna, Italy
  • Double Hit Lymphoma  |  Laurie Sehn, MD, MPH  |  BC Cancer, Vancouver, Canada
  • CAR T-Cell Therapy for Lymphoma  |  Sattva S. Neelapu, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Go To Session
6:45 AM - 7:45 AM (CDT)

MTP Session V: CML

Session Chair: Jerry Radich

  • Selecting the Right TKI | Jorge Cortés, MD | Georgia Cancer Center at Augusta University, Augusta, Georgia, USA
  • CML Management in Resource Limited Countries | Jerald P. Radich, MD | University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
  • Is NGS Ready for Clinical Practice: Advantages and Limitations | Simona Soverini, MD | University of Bologna, Bologna, Italy
Go To Session
6:45 AM - 7:45 AM (CDT)

MTP Session VI: MPN      

Session Chair: Uday Popat        
CASE STUDIES IN MPN: WHEN IS TREATMENT NECESSARY?        

  • A Young Woman with Thrombocytosis  |  Prithviraj Bose, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  • A Young Man with Polycythemia Vera and Fatigue  |  Gabriela Hobbs, MD  |  Massachusetts General Hospital, Boston, Massachusetts, USA
  • A Mildly Symptomatic Middle-Aged Woman with INT-1 Primary Myelofibrosis  |  Uday Popat, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Go To Session
6:45 AM - 7:45 AM (CDT)

MTP Session VII: MDS        

Session Chair: Koichi Takahashi

  • Pitfalls in Assessing Response to Treatment in MDS  |  Uwe Platzbecker, MD  |  Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany
  • The Spectrum of Clonal Hematopoiesis from CHIP to AML  |  Koichi Takahashi, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  • Challenges in Diagnosis and Risk Stratification of MDS  |  Aziz Nazha, MD  |  Cleveland Clinic, Cleveland, Ohio, USA
Go To Session
6:45 AM - 7:45 AM (CDT)

MTP Session VIII: MM        

Session Chair: Thomas Martin        

  • Latest Treatment Approaches in AL Amyloidosis  |  Suzanne Lentzsch, MD, PhD  |  Columbia University and at New York Presbyterian Hospital, New York, USA
  • Emerging Therapy  |  Thomas G. Martin, MD  |  University of California San Francisco, San Francisco, California, USA
Go To Session
6:45 AM - 7:45 AM (CDT)

MTP Session IX: CLL        

Session Chair: Emili Montserrat        

  • BTK and Monoclonal Antibodies  |  Carol Moreno, MD, PhD  |  Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
  • BTK and CIT  |  Philip A. Thompson, MB, BS  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  • BTK and BCL2  |  Nitin Jain, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Go To Session
6:45 AM - 7:45 AM (CDT)

MTP Session X: Cellular Therapy (No CME credit for this session)        

Session Chair: Susan Prockop        

  • CD19 CAR T Cells for Adults  |  David L. Porter, MD  |  University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, USA
  • EBV CTLs for PTLD– Ready for Prime Time  |  Susan Prockop, MD  |  Memorial Sloan Kettering Cancer Center, New York, New York, USA
  • Vaccines and Immunotherapy  |  David E. Avigan, MD  |  Beth Israel Deaconess Medical Center and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, USA
Go To Session
7:45 AM - 8:00 AM (CDT)

Exhibit Hall Experience

Go To Session
8:00 AM - 9:00 AM (CDT)

MTP Session XI: AML        

Session Chair: Courtney DiNardo        

  • Changing the Treatment Paradigm in AML  |  Daniel Pollyea, MD, MS  |  University of Colorado, Denver, Colorado, USA
  • Targeting the Microenvironment  |  Geoffrey L. Uy, MD  |  Washington University School of Medicine, St. Louis, Missouri, USA
  • Familial AML  |  Courtney D. DiNardo, MD, MSCE  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Go To Session
8:00 AM - 9:00 AM (CDT)

MTP Session XII: ALL      

Session Chair: Elias Jabbour        

  • How I Approach the Treatment of T-ALL in Adults in 2020  |  Nitin Jain, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  • How I Treat the Older Adult with B-ALL  |  Elias Jabbour, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  • How I Approach the Patient Who Has MRD Or Relapse After Transplant  |   Lori Muffly, MD  |  Stanford University Medical Center, Palo Alto, California, USA
Go To Session
8:00 AM - 9:00 AM (CDT)

MTP Session XIII: NHL      

Session Chair: Loretta Nastoupil        

  • Primary Mediastinal Large Cell Lymphoma  |  Pier Luigi Zinzani, MD  |  University of Bologna, Bologna, Italy
  • Role of Radiation Therapy in HL  |  Joachim Yahalom, MD, FACR  |  Memorial Sloan Kettering Cancer Center, New York, New York, USA
  • Chemo Free Regimens in Lymphoma  |  Loretta Nastoupil, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Go To Session
8:00 AM - 9:00 AM (CDT)

MTP Session XIV: NHL    

Session Chair: Ariela Noy        

  • Strategies for Developing Novel Therapies and Aggressive Lymphomas  |  Christopher R. Flowers, MD, MS  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  • Treatment of Early Stage DLBCL  |  Daniel O. Persky, MD  |  University of Arizona Cancer Center, Tucson, Arizona, USA
  • Burkitt Lymphoma  |  Ariela Noy, MD  |  Memorial Sloan Kettering Cancer Center, New York, New York, USA
Go To Session
8:00 AM - 9:00 AM (CDT)

MTP Session XV: CML  

Session Chair: Jerry Radich        

  • Selecting the Right TKI  |  Jorge Cortés, MD  |  Georgia Cancer Center at Augusta University, Augusta, Georgia, USA
  • CML Management in Resource Limited Countries  |  Jerald P. Radich, MD  |  University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
  • Is NGS Ready for Clinical Practice: Advantages and Limitations  |  Simona Soverini, MD  |  University of Bologna, Bologna, Italy
Go To Session
8:00 AM - 9:00 AM (CDT)

MTP Session XVI: MPN      

Session Chair: Uday Popat        
CASE STUDIES IN MPN: WHEN IS TREATMENT NECESSARY?        

  • A Young Woman with Thrombocytosis  |  Prithviraj Bose, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  • A Young Man with Polycythemia Vera and Fatigue  |  Gabriela Hobbs, MD  |  Massachusetts General Hospital, Boston, Massachusetts, USA
  • A Mildly Symptomatic Middle-Aged Woman with INT-1 Primary Myelofibrosis  |  Uday Popat, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Go To Session
8:00 AM - 9:00 AM (CDT)

MTP Session XVII: MDS    

Session Chair: Rami Komrokji        

  • How Do I Treat: Lower Risk MDS  |  Valeria Santini, MD  |  University of Florence, Florence, Italy
  • How Do I Treat: Higher Risk MDS  |  Rami Komrokji, MD  |  H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
  • How Do I Treat: MDS/MPN  |  Eric Padron, MD  |  H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
Go To Session
8:00 AM - 9:00 AM (CDT)

MTP Session XVIII: MM  

Session Chair: Sheeba Thomas        

  • Waldenstroms Macroglobunemia  |  Sheeba K. Thomas, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  • Bone Diseases and Supportive Care  |  Jens Hillengass, MD  |  Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
Go To Session
8:00 AM - 9:00 AM (CDT)

MTP Session XIX: CLL

Session Chair: Phil Thompson        

  • Managing BTK Inhibitor Toxicities  |  Alessandra Ferrajoli, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  • Managing BCL2 Toxicities  |  John Seymour, MBBS, FRACP, PhD  |  Peter MacCallum Cancer Centre & the Royal Melbourne Hospital, Melbourne, Australia
  • Managing Cellular Therapy Toxicities  |  Jae Park, MD  |  Memorial Sloan Kettering Cancer Center, New York, New York, USA
Go To Session
8:00 AM - 9:00 AM (CDT)

MTP Session XX: CT

Session Chair: Sergio Giralt

  • Point of Care CAR T Cells | Marcos de Lima, MD | UH Cleveland Medical Center, Cleveland, Ohio, USA
  • CAR vs Transplant for NHL | Richard Maziarz, MD | Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA
  • Role of CAR T Cells in Relapsed Myeloma | Andrzej Jakubowiak, MD, PhD | University of Chicago Medical Center, Chicago
Go To Session
9:00 AM - 9:15 AM (CDT)

Exhibit Hall Experience

Go To Session
9:15 AM - 11:41 AM (CDT)

Session I: Acute Lymphoblastic Leukemia

 
9:15 AM - 9:25 AM (CDT)

Session I: Acute Lymphoblastic Leukemia

Welcome and Opening Remarks | Sagar Lonial, MD, FACP | President, Society of Hematologic Oncology

Go To Session
9:25 AM - 9:43 AM (CDT)

Session I: Acute Lymphoblastic Leukemia

In Relapsed B-ALL, How Should We Best Sequence the New Targeted Agents? | Emily Curran, MD | The University of Cincinnati, Cincinnati, Ohio, USA

Go To Session
9:43 AM - 10:01 AM (CDT)

Session I: Acute Lymphoblastic Leukemia

Mini- Hyper – CVD Combinations for Older Adults: Results of Recent Trials and A Glimpse into the Future | Marlise R. Luskin, MD, MSCE | Dana Farber Cancer Institute, Boston, Massachusetts, USA

Go To Session
10:01 AM - 10:19 AM (CDT)

Session I: Acute Lymphoblastic Leukemia

Who Should Receive an Allogeneic Transplant in First Complete Remission? | Josep-Maria Ribera, MD, PhD | Catalan Institute of Oncology, Barcelona, Spain

Go To Session
10:19 AM - 10:37 AM (CDT)

Session I: Acute Lymphoblastic Leukemia

What’s the Latest Innovation in CAR-T Therapy? Fast-Off, Dual Targeting and Other New Tricks | Martin Pule, MB BCh, MRCP | Cancer Institute, University College London, London, United Kingdom

Go To Session
10:37 AM - 10:55 AM (CDT)

Session I: Acute Lymphoblastic Leukemia

Genomics of Drug Response in ALL: Predicting Response and Concerns for Triggering Relapse | Jun J. Yang, PhD |St. Jude Children's Research Hospital, Memphis, Tennessee, USA

Go To Session
10:55 AM - 11:31 AM (CDT)

Session I: Acute Lymphoblastic Leukemia

DEBATE: Is Less More? Intensive vs Non-Intensive Approach to Adults with Ph+ ALL | Nicholas Short, MD | Sabina Chiaretti, MD, PhD

Go To Session
11:31 AM - 11:41 AM (CDT)

Session I: Acute Lymphoblastic Leukemia

Oral Abstract - ALL-312 | Saleem Eldadah, MD | Princess Noorah Oncology Center, Ministry of the National Guard - Health Affairs, Jeddah, Saudi Arabia

Go To Session
11:41 AM - 1:11 PM (CDT)

Industry Expert Session IA

An Acute Myeloid Leukemia Treatment Option for Patients | Hetty Carraway, MD, MBA | Cleveland Clinic, Cleveland, Ohio, USA

Go To Session
11:41 AM - 1:11 PM (CDT)

Industry Expert Session IB

A CAR T-cell Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma TECARTUS™ (brexucabtageneautoleucel) Prescribing Information  | David Rizzieri, MD | Duke University School of Medicine, Durham, North Carolina, USA

Go To Session
12:41 PM - 1:11 PM (CDT)

Exhibit Hall Experience

Go To Session
1:11 PM - 1:31 PM (CDT)

Plenary Session I

Keynote Speaker: Immunotherapy for T-Cell ALL and T-NHL | John DiPersio, MD, PhD | Washington University, St. Louis, Missouri, USA

Go To Session
1:31 PM - 3:11 PM (CDT)

Session II: Myelodysplastic Syndromes

 
1:31 PM - 1:49 PM (CDT)

Session II: Myelodysplastic Syndromes

New Approaches for Anemia in MDS | Uwe Platzbecker, MD | Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany

Go To Session
1:49 PM - 2:07 PM (CDT)

Session II: Myelodysplastic Syndromes

Development of Oral HMAs for MDS | Guillermo Garcia-Manero, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Go To Session
2:07 PM - 2:25 PM (CDT)

Session II: Myelodysplastic Syndromes

Targeting BCL-2 in MDS | Amer Zeidan, MBBS | Yale Cancer Center, New Haven, Connecticut, USA

Go To Session
2:25 PM - 2:43 PM (CDT)

Session II: Myelodysplastic Syndromes

Targeting p53 in MDS | David Sallman, MD | H. Lee Moffitt Cancer Center, Tampa, Florida, USA

Go To Session
2:43 PM - 3:01 PM (CDT)

Session II: Myelodysplastic Syndromes

IDH inhibitors in MDS | Courtney D. DiNardo, MD, MSCE | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Go To Session
3:01 PM - 3:11 PM (CDT)

Session II: Myelodysplastic Syndromes

Oral Abstract - MDS-254 SF3B1 Splicing Mutation in the Context of Therapy-Related MDS | Virginia Volpe, MD | H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

Go To Session
3:11 PM - 3:41 PM (CDT)

Exhibit Hall Experience

Go To Session
3:41 PM - 3:59 PM (CDT)

Session III: Acute Myeloid Leukemia

State of the Art in AML | Laura C. Michaelis, MD | Medical College of Wisconsin, Milwaukee, Wisconsin, USA

Go To Session
3:41 PM - 6:15 PM (CDT)

Session III: Acute Myeloid Leukemia

 
3:59 PM - 4:17 PM (CDT)

Session III: Acute Myeloid Leukemia

Germline Mutations in AML | Coleman Lindsley, MD, PhD | Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Go To Session
4:17 PM - 4:35 PM (CDT)

Session III: Acute Myeloid Leukemia

Harnessing Apoptosis in AML | Marina Konopleva, MD, PhD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Go To Session
4:35 PM - 4:53 PM (CDT)

Session III: Acute Myeloid Leukemia

The Problem of Mutant P53 AML | David Sallman, MD | H. Lee Moffitt Cancer Center, Tampa, Florida, USA

Go To Session
4:53 PM - 5:11 PM (CDT)

Session III: Acute Myeloid Leukemia

Targeting CD123 in AML | Andrew A. Lane, MD, PhD | Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Go To Session
5:11 PM - 5:26 PM (CDT)

Session III: Acute Myeloid Leukemia

DEBATE: Fit Older Adults Between 60-75 in First Remission on Either Extreme of the Prognostic Spectrum Should Undergo Allo SCT | Edwin Pascal Alyea, MD | Duke University School of Medicine, Durham, North Carolina, USA

Go To Session
5:26 PM - 5:47 PM (CDT)

Session III: Acute Myeloid Leukemia

DEBATE: Fit Older Adults Between 60-75 in First Remission on Either Extreme of the Prognostic Spectrum Should Not Undergo Allo SCT | Uma Borate, MD, MS | Oregon Health & Science University, Portland, Oregon, USA

Go To Session
5:47 PM - 6:05 PM (CDT)

Session III: Acute Myeloid Leukemia

Novel Antibodies in AML | Marion Subklewe, MD | Ludwig-Maximilians-University of Munich, Munich, Germany

Go To Session
6:05 PM - 6:15 PM (CDT)

Session III: Acute Myeloid Leukemia

Oral Abstract - AML-063 A Randomized, Double-Blind, Placebo-Controlled Study in Treatment-Naïve Patients with Acute Myeloid Leukemia Ineligible for Intensive Therapy-Viale-A | Courtney D. DiNardo, MD, MSCE | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Go To Session
6:15 PM - 8:15 PM (CDT)

Poster Session & Awards

Chat with Poster Presenters and congratulate the Award winners.

Go To Session
8:15 PM - 9:45 PM (CDT)

Independent Satellite Symposium I

Relapsed/Refractory Multiple Myeloma: What’s Next for Patients? | Jesus Berdeja, MD, Tennessee Oncology | Joshua Richter, MD, Mount Sinai

Go To Session
Thursday, September 10, 2020
6:15 AM - 7:45 AM (CDT)

Independent Satellite Symposium II

The Evolving Therapeutic Landscape in Relapsed Refractory Multiple Myeloma |Sagar Lonial, MD, FACP | Emory University, Atlanta, USA – Chair | Adam Cohen, MD | University of Pennsylvania, Philadelphia, USA | Shaji Kumar, MD | Mayo Clinic, Rochester, Minnesota, USA

Go To Session
6:45 AM - 7:45 AM (CDT)

Breakfast with the Expert I

CAR T for Myeloid Leukemias – Current Status | Elizabeth L. Budde, MD, PhD | City of Hope National Medical Center, Duarte, California, USA

Go To Session
7:45 AM - 8:00 AM (CDT)

Exhibit Hall Experience

Go To Session
8:00 AM - 8:18 AM (CDT)

Session IV: Myeloproliferative Neoplasms

Genomics in Myelofibrosis: Practical Guidelines for Its Use in Clinical Practice  | Raajit K. Rampal, MD, PhD | Memorial Sloan Kettering Cancer Center, New York, New York, USA

Go To Session
8:00 AM - 10:10 AM (CDT)

Session IV: Myeloproliferative Neoplasms

 
8:18 AM - 8:36 AM (CDT)

Session IV: Myeloproliferative Neoplasms

New Therapies in Development for Myelofibrosis  | Srdan Verstovsek, MD, PhD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Go To Session
8:36 AM - 8:54 AM (CDT)

Session IV: Myeloproliferative Neoplasms

Improved Outcomes with Transplant for MPN  | Uday Popat, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Go To Session
8:54 AM - 9:12 AM (CDT)

Session IV: Myeloproliferative Neoplasms

CASE PRESENTATION: Thrombosis in PV: How to Predict and How to Reduce the Risk  | Gabriela Hobbs, MD | Massachusetts General Hospital, Boston, Massachusetts, USA

Go To Session
9:12 AM - 9:30 AM (CDT)

Session IV: Myeloproliferative Neoplasms

CASE PRESENTATION: Post PV and Post ET MF: What A Doctor Needs to Know | Laura C. Michaelis, MD | Medical College of Wisconsin, Milwaukee, Wisconsin, USA

Go To Session
9:30 AM - 9:40 AM (CDT)

Session IV: Myeloproliferative Neoplasms

Oral Abstract - MPN-188 Myeloablative Regimen in Myelofibrosis (MF): Long-Term Outcomes and Analysis of Prognostic Factors | Jacinth Joseph, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Go To Session
9:40 AM - 10:10 AM (CDT)

Exhibit Hall Experience

Go To Session
10:10 AM - 12:26 PM (CDT)

Session V: Multiple Myeloma

 
10:10 AM - 10:28 AM (CDT)

Session V: Multiple Myeloma

Frontline Therapy for Frail Older Patients | Brea C. Lipe, MD | The University of Rochester, Rochester, New York, USA

Go To Session
10:28 AM - 10:43 AM (CDT)

Session V: Multiple Myeloma

DEBATE: Frontline Therapy for Fit MM Patients Should Include an Antibody | Peter M. Voorhees, MD | Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA

Go To Session
10:43 AM - 11:04 AM (CDT)

Session V: Multiple Myeloma

DEBATE: Frontline Therapy for Fit MM Patients Should NOT Include an Antibody | Thomas G. Martin, MD | University of California San Francisco, San Francisco, California, USA

Go To Session
11:04 AM - 11:19 AM (CDT)

Session V: Multiple Myeloma

DEBATE: Smoldering MM Should Be Treated Early | Maria-Victoria Mateos, MD, PhD | University Hospital of Salamanca, Spain

Go To Session
11:19 AM - 11:40 AM (CDT)

Session V: Multiple Myeloma

DEBATE: Smoldering MM Should NOT Be Treated Early | Angela Dispenzieri, MD | Mayo Clinic Rochester, Rochester, Minnesota, USA

Go To Session
11:40 AM - 11:58 AM (CDT)

Session V: Multiple Myeloma

Role of HDT in Current Treatment for MM | Ajay K. Nooka, MD, MPH, FACP | Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA

Go To Session
11:58 AM - 12:16 PM (CDT)

Session V: Multiple Myeloma

Management of Early Relapse | Robert Z. Orlowski, MD, PhD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Go To Session
12:16 PM - 12:26 PM (CDT)

Session V: Multiple Myeloma

Oral Abstract - MM-350 Subgroup Analysis of GRIFFIN in African American/Black Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) | Ajay K. Nooka, MD, MPH, FACP | Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA

Go To Session
12:26 PM - 1:56 PM (CDT)

Industry Expert Session IIA

IMMUNO-ONCOLOGY AND MDS: Current Knowledge and Future Perspectives | Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA |Guillermo Garcia-Manero, MD, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Go To Session
12:26 PM - 1:56 PM (CDT)

Industry Expert Session IIB

Intervening with Jakafi (ruxolitinib) to Achieve Durable Count Control: Real World Patient Case Discussion Focus on Adults With Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea | David Rizzieri, MD | Duke University School of Medicine, Durham, North Carolina, USA

Go To Session
1:56 PM - 2:16 PM (CDT)

Plenary Session II

BCMA Directed Therapy for MM | Nikhil C. Munshi, MD | Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Go To Session
2:16 PM - 4:44 PM (CDT)

Session VI: Chronic Lymphocytic Leukemia

 
2:16 PM - 2:34 PM (CDT)

Session VI: Chronic Lymphocytic Leukemia

Next Generation of BCR Inhibitors | Paolo Ghia, MD, PhD | Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy

Go To Session
2:34 PM - 2:52 PM (CDT)

Session VI: Chronic Lymphocytic Leukemia

Measuring Residual Disease, Clinical Implications | William Wierda, MD, PhD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Go To Session
2:52 PM - 3:10 PM (CDT)

Session VI: Chronic Lymphocytic Leukemia

What Is Fitness in the Era of Targeted Agents | Alessandra Tedeschi, MD | Niguarda Cancer Center, ASST Grande Ospedale Metropolitan Niguarda, Milan, Italy

Go To Session
3:10 PM - 3:25 PM (CDT)

Session VI: Chronic Lymphocytic Leukemia

DEBATE: BTK Inhibitor Is the Best Frontline Option for CLL | John C. Byrd, MD | The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA

Go To Session
3:25 PM - 3:46 PM (CDT)

Session VI: Chronic Lymphocytic Leukemia

DEBATE: BCL2 Inhibitor Is the Best Frontline Option for CLL | Michael Hallek, MD | University Hospital of Cologne, Cologne, Germany

Go To Session
3:46 PM - 4:04 PM (CDT)

Session VI: Chronic Lymphocytic Leukemia

Cellular Therapies in CLL | Elizabeth J. Shpall, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Go To Session
4:04 PM - 4:14 PM (CDT)

Session VI: Chronic Lymphocytic Leukemia

Oral Abstract - CLL-091 ASCEND Final Results in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) | Paolo Ghia, MD, PhD | Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy

Go To Session
4:14 PM - 4:44 PM (CDT)

Exhibit Hall Experience

Go To Session
4:44 PM - 5:44 PM (CDT)

Industry Expert Session III

A Treatment Option for Adult Patients With Newly Diagnosed CP Ph+ CML or Patients Resistant/Intolerant to Prior TKI Therapy | Jorge Cortés, MD | Georgia Cancer Center at Augusta University, Augusta, Georgia, USA

Go To Session
5:44 PM - 6:44 PM (CDT)

Industry Expert Session IV

A Case-based Discussion on Improving Outcomes in Patients with Newly Diagnosed Secondary AML | Usama Gergis, MD, MBA | Weill Cornell Medical College, New York, New York, USA

Go To Session
6:44 PM - 8:24 PM (CDT)

Independent Satellite Symposium III

Myeloproliferative Neoplasms: Integrating New Therapies Into Challenging Case Scenarios | Prithviraj Bose, MD - Chair | Ruben Mesa, MD | Raajit K. Rampal, MD, PhD

Go To Session
Friday, September 11, 2020
6:15 AM - 7:45 AM (CDT)

Independent Satellite Symposium IV

Achieving Innovation in CLL Care With BTK Inhibitors: Selection, Safety, and Sequencing Across the Disease Continuum | William G. Wierda, MD, PhD | Philip A. Thompson, MB, MS | The University of Texas MD Anderson Cancer Center

Go To Session
6:45 AM - 7:45 AM (CDT)

Breakfast with the Expert II

How to Move Beyond RCHOP | Sandeep S. Dave, MD, MS | Duke University School of Medicine, Durham, North Carolina, USA

Go To Session
7:45 AM - 8:00 AM (CDT)

Exhibit Hall Experience

Go To Session
8:00 AM - 8:18 AM (CDT)

Session VII: Hodgkin Lymphoma

Newly Diagnosed HL | David J. Straus, MD | Memorial Sloan Kettering Cancer Center, New York, New York, USA

Go To Session
8:00 AM - 8:46 AM (CDT)

Session VII: Hodgkin Lymphoma

 
8:18 AM - 8:36 AM (CDT)

Session VII: Hodgkin Lymphoma

Relapsed HL | Alex F. Herrera, MD | City of Hope, Duarte, California, USA

Go To Session
8:36 AM - 8:46 AM (CDT)

Session VII: Hodgkin Lymphoma

Oral Abstract - HL-323 Outcomes of First-Line Treatment in Patients with Advanced Clinical Stage Classic Hodgkin Lymphoma and Human Immunodeficiency Virus Infection | Juan José Del Moral, MD | Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

Go To Session
8:46 AM - 9:04 AM (CDT)

Session VIII: T-Cell Lymphoma

Pathology and Pathogenesis of T Cell Lymphoma | Francisco Vega, MD PhD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Go To Session
8:46 AM - 9:50 AM (CDT)

Session VIII: T-Cell Lymphoma

 
9:04 AM - 9:22 AM (CDT)

Session VIII: T-Cell Lymphoma

Newly Diagnosed | Kerry Savage, MD | BC Cancer, Vancouver, Canada

Go To Session
9:22 AM - 9:40 AM (CDT)

Session VIII: T-Cell Lymphoma

Relapsed T Cell Lymphoma | Steven M. Horwitz, MD | Memorial Sloan Kettering Cancer Center, New York, New York, USA

Go To Session
9:40 AM - 9:50 AM (CDT)

Session VIII: T-Cell Lymphoma

Oral Abstract - TCL-127 Impact of Concomitant Steroids on Efficacy in MAVORIC Trial | Larisa J. Geskin, MD, FAAD | New York Presbyterian Hospital, New York, NY, USA

Go To Session
9:50 AM - 10:20 AM (CDT)

Exhibit Hall Experience

Go To Session
10:20 AM - 10:38 AM (CDT)

Session IX: Indolent B-Cell Lymphoma

Management of Newly Diagnosed FL | Mathias J. Rummel, MD, PhD | Justus-Liebig University-Hospital, Giessen, Germany

Go To Session
10:20 AM - 11:42 AM (CDT)

Session IX: Indolent B-Cell Lymphoma

 
10:20 AM - 11:42 AM (CDT)

Session IX: Indolent B-Cell Lymphoma

 
10:38 AM - 10:56 AM (CDT)

Session IX: Indolent B-Cell Lymphoma

Relapsed FL | Nathan H. Fowler, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Go To Session
10:56 AM - 11:14 AM (CDT)

Session IX: Indolent B-Cell Lymphoma

Marginal Zone Lymphoma | Emanuele Zucca, MD | Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Go To Session
11:14 AM - 11:32 AM (CDT)

Session IX: Indolent B-Cell Lymphoma

Waldenstrom | Morie A. Gertz, MD | Mayo Clinic, Rochester, Minnesota, USA

Go To Session
11:32 AM - 11:42 AM (CDT)

Session IX: Indolent B-Cell Lymphoma

Oral Abstract - IBCL-344 Marginal Zone Lymphoma: Epidemiology and Outcomes in a Mexican Center | Rosana Córdova, MD | Instituto Nacional de Cancerología, Mexico City, Mexico

Go To Session
11:42 AM - 1:12 PM (CDT)

Industry Expert Session VA

Redefining Approaches in Frontline Chronic Lymphocytic Leukemia (CLL) Treatment Imbruvica® + Rituximab vs FCR: Head-to-Head- Data in Frontline CLL/SLL | Nakhle Saba, MD, Tulane University, New Orleans, Louisiana, USA | Ruemu Birhiray, MD, Hematology Oncology of Indiana, Indianapolis, Indiana

Go To Session
11:42 AM - 1:12 PM (CDT)

Industry Expert Session VB

Explore Yescarta®:  CAR T Therapy, for Patients in Your Practice | John Pagel, MD, PhD | Swedish Cancer Institute, Seattle, Washington, USA

Go To Session
1:12 PM - 1:32 PM (CDT)

Plenary Session III

My Take on Prognostication and Management of Essential Thrombocythemia | Ayalew Tefferi, MD | Mayo Clinic Rochester, Rochester Minnesota, USA

Go To Session
1:32 PM - 3:06 PM (CDT)

Session X: Aggressive B-Cell Lymphoma

 
1:32 PM - 1:50 PM (CDT)

Session X: Aggressive B-Cell Lymphoma

Novel Immunotherapeutic Agents in Aggressive B-NHL | Martin Hutchings, MD, PhD | The Finsen Center, National Hospital Copenhagen University Hospital, Copenhagen, Denmark

Go To Session
1:50 PM - 2:08 PM (CDT)

Session X: Aggressive B-Cell Lymphoma

Relapsed DLBCL | Sonali M. Smith, MD, FASCO | The University of Chicago, Chicago, Illinois, USA

Go To Session
2:08 PM - 2:26 PM (CDT)

Session X: Aggressive B-Cell Lymphoma

CAR T Cells | Peter Riedell, MD | University of Chicago Medicine, Chicago, Illinois, USA

Go To Session
2:26 PM - 2:36 PM (CDT)

Session X: Aggressive B-Cell Lymphoma

Oral Abstract - ABCL-256 Role of Radiotherapy Differs Between Stages for Primary Bone Large B-Cell Lymphoma: A Real-World Study | Shengling Ma, MD | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Go To Session
2:36 PM - 3:06 PM (CDT)

Exhibit Hall Experience

Go To Session
3:06 PM - 3:52 PM (CDT)

Session XI: Mantle Cell Lymphoma

 
3:06 PM - 3:24 PM (CDT)

Session XI: Mantle Cell Lymphoma

Frontline Treatment of Mantle Cell Lymphoma | Steven Le Gouill, MD, PhD | Nantes University Hospital, Nantes, France

Go To Session
3:24 PM - 3:42 PM (CDT)

Session XI: Mantle Cell Lymphoma

Relapsed MCL | Jonathon B. Cohen MD, MS | Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA

Go To Session
3:42 PM - 3:52 PM (CDT)

Session XI: Mantle Cell Lymphoma

Oral Abstract - MCL-129 First-Line Targeted Combination in MCL for Older Patients or Those with a TP53 Mutation: Ongoing Open-Label Arm of the PCYC-1143 Phase 3 SYMPATICO Study | Michael L. Wang, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Go To Session
3:52 PM - 4:10 PM (CDT)

Session XII: Cellular Therapy

Adding Vaccines to the Immunotherapy Cocktail | David E. Avigan, MD | Beth Israel Deaconess Medical Center and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, USA

Go To Session
3:52 PM - 4:56 PM (CDT)

Session XII: Cellular Therapy

 
4:10 PM - 4:28 PM (CDT)

Session XII: Cellular Therapy

New CAR Designs | Renier J. Brentjens, MD, PhD | Memorial Sloan Kettering Cancer Center, New York, New York, USA

Go To Session
4:28 PM - 4:46 PM (CDT)

Session XII: Cellular Therapy

Optimizing Lymphodepletion Prior to CAR T Cell Therapy   | Elizabeth L. Budde, MD, PhD | City of Hope National Medical Center, Duarte, California, USA

Go To Session
4:46 PM - 4:56 PM (CDT)

Session XII: Cellular Therapy

Oral Abstract - CT-279 Story of Success of Haploidentical Hematopoietic Stem Cell Transplantation in Aplastic Anemia: A Systematic Review and Meta-Analysis of Clinical Outcome | Ghada ELGohary, MD | Ain Shams University, Cairo, Egypt

Go To Session
4:56 PM - 5:56 PM (CDT)

Industry Expert Session VI

XOSPATA® (gilteritmnib): A Targeted Therapeutic Approach for Relapsed/Refractory FLT3m+ AML Patients | Naval Daver, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Go To Session
5:56 PM - 7:26 PM (CDT)

Independent Satellite Symposium V

The Rise of Novel Antibodies in Multiple Myeloma: Exploring the Present and Future of Antibody-based Treatment From CD38 to BCMA | Sagar Lonial, MD, FACP | Robert Z. Orlowski, MD, PhD

Go To Session
6:56 PM - 8:26 PM (CDT)

Independent Satellite Symposium VI

Treating Multiple Myeloma in 2020 – Best Approaches to Optimizing Patient Outcomes | Robert Z. Orlowski, MD, PhD - Chair | María-Victoria Mateos, MD, PhD | Paul Richardson, MD

Go To Session
Saturday, September 12, 2020
6:45 AM - 7:45 AM (CDT)

Breakfast with the Expert III

CML Update | Michael Deininger, MD, PhD | Huntsman Cancer Hospital, The University of Utah, Salt Lake City, Utah, USA

Go To Session
6:45 AM - 7:45 AM (CDT)

Independent Satellite Symposium VII

Discover the Role of Two Immunotherapies in Myeloma Treatment | Melhem M. Solh, MD | Northside Hospital Blood and Marrow Transplant and Leukemia Program

Go To Session
7:45 AM - 8:00 AM (CDT)

Exhibit Hall Experience

Go To Session
8:00 AM - 8:18 AM (CDT)

Session XIII: Chronic Myeloid Leukemia

CML: State of the Art Update | Delphine Rea, MD, PhD | Hôpital Saint Louis, Paris, France

Go To Session
8:00 AM - 9:40 AM (CDT)

Session XIII: Chronic Myeloid Leukemia

 
8:18 AM - 8:36 AM (CDT)

Session XIII: Chronic Myeloid Leukemia

New Therapeutic Options in CML | Jorge Cortés, MD | Georgia Cancer Center at Augusta University, Augusta, Georgia, USA

Go To Session
8:36 AM - 8:54 AM (CDT)

Session XIII: Chronic Myeloid Leukemia

Update on CML-Like Disorders | Nick Cross, MA, PhD, FRCPath | University of Southampton, Salisbury, United Kingdom

Go To Session
8:54 AM - 9:12 AM (CDT)

Session XIII: Chronic Myeloid Leukemia

Case Studies: The Challenges of TFR | Timothy P. Hughes, MD, FRACP, FRCPA | South Australian Health and Medical Research Institute, Adelaide, Australia

Go To Session
9:12 AM - 9:30 AM (CDT)

Session XIII: Chronic Myeloid Leukemia

The Molecular Complexity of CML | Jerald P. Radich, MD | University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

Go To Session
9:30 AM - 9:40 AM (CDT)

Session XIII: Chronic Myeloid Leukemia

Oral Abstract - CML-109 Exploratory Biomarker Analysis From ENESTnd: Gene Expression Signature Distinguishes Deep Molecular Response (DMR) From Poor Response in Chronic Myeloid Leukemia (CML) | Jerald P. Radich, MD | University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

Go To Session
9:40 AM - 10:10 AM (CDT)

Exhibit Hall Experience

Go To Session
10:10 AM - 12:20 PM (CDT)

Session XIV: Next Questions

 
10:10 AM - 10:20 AM (CDT)

Session XIV: Next Questions

Next Questions: Acute Lymphoblastic Leukemia | Selina M. Luger, MD | University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, USA

Go To Session
10:20 AM - 10:30 AM (CDT)

Session XIV: Next Questions

Next Questions: Acute Myeloid Leukemia | Amer Zeidan, MBBS | Yale Cancer Center, New Haven, Connecticut, USA

Go To Session
10:30 AM - 10:40 AM (CDT)

Session XIV: Next Questions

Next Questions: Cellular Therapy | Sergio Giralt, MD | Memorial Sloan Kettering Cancer Center, New York, New York, USA

Go To Session
10:40 AM - 10:50 AM (CDT)

Session XIV: Next Questions

Next Questions: Myelodysplastic Syndromes | Guillermo Garcia-Manero, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Go To Session
10:50 AM - 11:00 AM (CDT)

Session XIV: Next Questions

Next Questions: Chronic Myeloid Leukemia | Michael Deininger, MD, PhD | Huntsman Cancer Hospital, The University of Utah, Salt Lake City, Utah, USA

Go To Session
11:00 AM - 11:10 AM (CDT)

Session XIV: Next Questions

Next Questions: Aggressive B-Cell Lymphoma | Sandeep S. Dave, MD, MS | affiliation

Go To Session
11:10 AM - 11:20 AM (CDT)

Session XIV: Next Questions

Next Questions: Indolent B-Cell Lymphoma | Robert Marcus, MA, FRCP, FRCPath | Leaders in Oncology Care, London, United Kingdom

Go To Session
11:20 AM - 11:30 AM (CDT)

Session XIV: Next Questions

Next Questions: T-Cell Lymphoma | Kerry Savage, MD | BC Cancer, Vancouver, Canada

Go To Session
11:30 AM - 11:40 AM (CDT)

Session XIV: Next Questions

Next Questions: Mantle Cell Lymphoma | Jonathon B. Cohen, MD, MS | Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA

Go To Session
11:40 AM - 11:50 AM (CDT)

Session XIV: Next Questions

Next Questions: Hodgkin Lymphoma | David J. Straus, MD | Memorial Sloan Kettering Cancer Center, New York, New York, USA

Go To Session
11:50 AM - 12:00 PM (CDT)

Session XIV: Next Questions

Next Questions: Multiple Myeloma | Sagar Lonial, MD, FACP | Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA

Go To Session
12:00 PM - 12:10 PM (CDT)

Session XIV: Next Questions

Next Questions: Chronic Lymphocytic Leukemia | Jennifer R. Brown, MD, PhD | Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Go To Session
12:10 PM - 12:20 PM (CDT)

Session XIV: Next Questions

Next Questions: Myeloproliferative Neoplasms | Dr. Prithviraj Bose, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Go To Session
(CDT)

None (Select only if you will not be attending any of the sessions listed above)